Therefore, it is well-established that Mcl-1 plays critical roles in venetoclax resistance, and combination treatment of venetoclax with Mcl-1 inhibitors induces synergistic anti-tumor activity and eradicates venetoclax-resistant cancers (Ramsey et al. 2018; Luedtke et al. 2017). This evidence concerns the gene MCL1 and cancer.